 I announce that the Senator from Colorado (Mr. Bennet),  the Senator from New Jersey (Mr. Booker), the Senator from California  (Ms. Harris), the Senator from New Hampshire (Ms. Hassan), the Senator  from Minnesota (Ms. Klobuchar), the Senator from Vermont (Mr. Sanders),  the Senator from Hawaii (Mr. Schatz), the Senator from Michigan (Ms.  Stabenow), the Senator from Massachusetts  [[Page S5916]]  (Ms. Warren), and the Senator from Rhode Island (Mr. Whitehouse) are  necessarily absent.    Mr. President, I ask unanimous consent that the text of  the bill be printed in the Record.   There being no objection, the text of the bill was ordered to be  printed in the Record, as follows:                                  S. 2650         Be it enacted by the Senate and House of Representatives of       the United States of America in Congress assembled,       SECTION 1. SHORT TITLE.         This Act may be cited as the ``Medicare Prescription Drug       Savings and Choice Act of 2019''.       SEC. 2. ESTABLISHMENT OF MEDICARE OPERATED PRESCRIPTION DRUG                     PLAN OPTION.         (a) In General.--Subpart 2 of part D of title XVIII of the       Social Security Act is amended by inserting after section       1860D-11 (42 U.S.C. 1395w-111) the following new section:              ``medicare operated prescription drug plan option         ``Sec. 1860D-11A.  (a) In General.--Notwithstanding any       other provision of this part, for each year (beginning with       2021), in addition to any plans offered under section 1860D-      11, the Secretary shall offer one or more Medicare operated       prescription drug plans (as defined in subsection (d)) with a       service area that consists of the entire United States and       shall enter into negotiations in accordance with subsection       (c) with pharmaceutical manufacturers to reduce the purchase       cost of covered part D drugs for eligible part D individuals       who enroll in such a plan.        ``(b) Enrollment.--Notwithstanding subparagraphs (C) and       (D) of section 1860D-1(b)(1), a Medicare operated       prescription drug plan offered under this section shall serve       as the default prescription drug plan for all part D       enrollees unless another prescription drug plan is selected.        ``(c) Negotiations.--Notwithstanding section 1860D-11(i),       for purposes of offering a Medicare operated prescription       drug plan under this section, the Secretary shall negotiate       with pharmaceutical manufacturers with respect to the       purchase price of covered part D drugs in a Medicare operated       prescription drug plan and shall encourage the use of more       affordable therapeutic equivalents to the extent such       practices do not override medical necessity as determined by       the prescribing physician. To the extent practicable and       consistent with the previous sentence, the Secretary shall       implement negotiation and incentive strategies similar to       those used by other Federal purchasers of prescription drugs       to reduce the purchase cost of covered Part D drugs, and       other strategies, as described in subsection (f), which may       include the use of a pricing scale based on an international       price index.        ``(d) Medicare Operated Prescription Drug Plan Defined.--      For purposes of this part, the term `Medicare operated       prescription drug plan' means a comprehensive prescription       drug plan that offers qualified prescription drug coverage       and access to negotiated prices described in section 1860D-      2(a)(1)(A). Such a plan may offer supplemental prescription       drug coverage in the same manner as other qualified       prescription drug coverage offered by other prescription drug       plans.        ``(e) Monthly Beneficiary Premium.--        ``(1) Qualified prescription drug coverage.--The monthly       beneficiary premium for qualified prescription drug coverage       and access to negotiated prices described in section 1860D-      2(a)(1)(A) to be charged under a Medicare operated       prescription drug plan shall be uniform nationally. Such       premium for months in 2021 and each succeeding year shall be       based on the average monthly per capita actuarial cost of       offering the Medicare operated prescription drug plan for the       year involved, including administrative expenses.        ``(2) Supplemental prescription drug coverage.--Insofar as       a Medicare operated prescription drug plan offers       supplemental prescription drug coverage, the Secretary may       adjust the amount of the premium charged under paragraph (1).        ``(f) Use of Negotiation and Benefit Design Incentives.--        ``(1) In general.--With respect to the operation of a       Medicare operated prescription drug plan and in negotiating       with respect to the purchase price of covered part D drugs in       such plan, the Secretary shall reward value, increase       appropriate use of drugs, and ensure patient safety and       access to medications.        ``(2) Role of ahrq.--The Director of the Agency for       Healthcare Research and Quality,  [[Page S5925]]       in coordination with the Administrator of the Centers for       Medicare & Medicaid Services, shall be responsible for       assessing the clinical benefit of covered part D drugs and       making recommendations to the Secretary regarding the       negotiated prices of covered drugs and any appropriate       tiering or incentive strategies under the plan. In conducting       such assessments and making such recommendations, the       Director shall carry out the following activities:        ``(A) Consider the comparable international price of such       drugs based upon the median retail list price of such drug       (which shall be, as practicable, the volume-weighted price       for comparable units and dosage forms) among a category of at       least the following peer reference countries: Canada, the       United Kingdom, France, Japan, Australia, and Germany.        ``(B) Consider safety concerns and post-market data,       including those identified by the Food and Drug       Administration and from national health registries.        ``(C) Use available data and evaluations, including from       research supported by the National Institutes of Health, with       priority given to randomized controlled trials, to examine       clinical effectiveness, comparative effectiveness, safety,       and enhanced compliance with a drug regimen.        ``(D) Use the same classes of drugs developed by United       States Pharmacopeia for this part.        ``(E) Consider evaluations made by--        ``(i) the Director under section 1013 of the Medicare       Prescription Drug, Improvement, and Modernization Act of       2003;        ``(ii) other Federal entities, such as the Secretary of       Veterans Affairs; and        ``(iii) other private and public entities, which may       include the Drug Effectiveness Review Project and Medicaid       programs.        ``(F) Consider recommendations made by the advisory       committee pursuant to paragraph (3)(F).        ``(G) Recommend to the Secretary those drugs in a class       that provide a greater clinical benefit, including fewer       safety concerns or less risk of side-effects, than another       drug in the same class.        ``(3) Use of advisory committee.--        ``(A) In general.--The Secretary shall establish and       appoint an advisory committee (in this paragraph referred to       as the `advisory committee')--        ``(i) to review petitions from drug manufacturers, health       care provider organizations, patient groups, and other       entities regarding negotiated prices; and        ``(ii) to recommend any changes in order to further       negotiations with respect to such prices.        ``(B) Composition.--Subject to subparagraph (C), the       advisory committee shall be composed of 9 members and shall       include representatives of physicians, pharmacists,       consumers, and others with expertise in evaluating       prescription drugs. The Secretary shall select members based       on their knowledge of pharmaceuticals and the Medicare       population. Members shall be deemed to be special Government       employees for purposes of applying the conflict of interest       provisions under section 208 of title 18, United States Code,       and no waiver of such provisions for such a member shall be       permitted.        ``(C) Banned individuals.--        ``(i) Drug company lobbyists.--No former registered drug       manufacturer lobbyist--         ``(I) may be appointed to the advisory committee; or        ``(II) may be employed by the advisory committee during the       6-year period beginning on the date on which the registered       lobbyist terminates its registration in accordance with       section 4(d) of the Lobbying Disclosure Act of 1995 (2 U.S.C.       1603(d)) or the agent terminates its status, as applicable.         ``(ii) Senior executives of law-breaking companies.--No       former senior executive of a covered entity (as defined in       clause (iii))--         ``(I) may be appointed to the Advisory Committee; or        ``(II) may be employed by the Advisory Committee during the       6-year period beginning on the later of--         ``(aa) the date of the settlement described in item (aa) of       clause (iii)(II); or        ``(bb) the date on which the enforcement action described       in item (bb) of such clause has concluded.        ``(iii) Covered entity.--The term `covered entity' means       any entity that is--         ``(I) a drug manufacturer; and        ``(II)(aa) operating under Federal settlement including a       Federal consent decree; or        ``(bb) the subject of an enforcement action in a court of       the United States or by an agency.         ``(D) Consultation.--The advisory committee shall consult,       as necessary, with physicians who are specialists in treating       the disease for which a drug is being considered.        ``(E) Request for studies.--The advisory committee may       request the Agency for Healthcare Research and Quality or an       academic or research institution to study and make a report       on a petition described in subparagraph (A)(i) in order to       assess cost-effectiveness, clinical effectiveness,       comparative effectiveness, safety, and compliance with a drug       regimen.        ``(F) Recommendations.--The advisory committee shall make       recommendations to the Director of the Agency for Healthcare       Research and Quality regarding the appropriate price at which       to begin negotiations on a part D drug pursuant to this       section.        ``(G) Limitations on review of manufacturer petitions.--The       advisory committee shall not review a petition of a drug       manufacturer under subparagraph (A)(i) with respect to a       covered part D drug unless the petition is accompanied by the       following:        ``(i) Raw data from clinical trials on the safety and       effectiveness of the drug.        ``(ii) Any data from clinical trials conducted using active       controls on the drug or drugs that are the current standard       of care.        ``(iii) Any available data on comparative effectiveness of       the drug.        ``(iv) Any other information the Secretary requires for the       advisory committee to complete its review.        ``(g) Informing Beneficiaries.--The Secretary shall take       steps to inform part D eligible individuals not previously       enrolled in a Medicare operated drug plan (including such       individuals who are newly eligible to enroll under this part)       regarding the enrollment of such individual in a Medicare       operated drug plan in accordance with this section, including       providing information in the annual handbook and adding       information to the official public Medicare website related       to prescription drug coverage available through this part.        ``(h) Application of All Other Requirements for       Prescription Drug Plans.--Except as specifically provided in       this section, any Medicare operated drug plan shall meet the       same requirements as apply to any other prescription drug       plan, including the requirements of section 1860D-4(b)(1)       relating to assuring pharmacy access.''.        (b) Conforming Amendments.--        (1) Section 1860D-3(a) of the Social Security Act (42       U.S.C. 1395w-103(a)) is amended by adding at the end the       following new paragraph:        ``(4) Availability of the medicare operated prescription       drug plan.--A Medicare operated prescription drug plan (as       defined in section 1860D-11A(d)) shall be offered nationally       in accordance with section 1860D-11A.''.        (2)(A) Section 1860D-3 of the Social Security Act (42       U.S.C. 1395w-103) is amended by adding at the end the       following new subsection:        ``(c) Provisions Only Applicable in 2006 Through 2020.--The       provisions of this section shall only apply with respect to       2006 through 2020.''.        (B) Section 1860D-11(g) of such Act (42 U.S.C. 1395w-      111(g)) is amended by adding at the end the following new       paragraph:        ``(8) No authority for fallback plans after 2020.--A       fallback prescription drug plan shall not be available after       December 31, 2020.''.        (3) Section 1860D-13(c)(3) of the Social Security Act (42       U.S.C. 1395w-113(c)(3)) is amended--        (A) in the heading, by inserting ``and medicare operated       prescription drug plans'' after ``Fallback plans''; and        (B) by inserting ``or a Medicare operated prescription drug       plan'' after ``a fallback prescription drug plan''.        (4) Section 1860D-16(b)(1) of the Social Security Act (42       U.S.C. 1395w-116(b)(1)) is amended--        (A) in subparagraph (C), by striking ``and'' after the       semicolon at the end;        (B) in subparagraph (D), by striking the period at the end       and inserting ``; and''; and        (C) by adding at the end the following new subparagraph:        ``(E) payments for expenses incurred with respect to the       operation of Medicare operated prescription drug plans under       section 1860D-11A.''.        (5) Section 1860D-41(a) of the Social Security Act (42       U.S.C. 1395w-151(a)) is amended by adding at the end the       following new paragraph:        ``(19) Medicare operated prescription drug plan.--The term       `Medicare operated prescription drug plan' has the meaning       given such term in section 1860D-11A(d).''.        (c) Rule of Construction.--Nothing in this section shall be       interpreted to supersede any other negotiation authority       granted to the Secretary under Federal law with respect to       prescription drug prices.       SEC. 3. IMPROVED APPEALS PROCESS UNDER THE MEDICARE OPERATED                     PRESCRIPTION DRUG PLAN.         Section 1860D-4(h) of the Social Security Act (42 U.S.C.       1305w-104(h)) is amended by adding at the end the following       new paragraph:        ``(4) Appeals process for medicare operated prescription       drug plan.--        ``(A) In general.--The Secretary shall develop a well-      defined process for appeals for denials of benefits under       this part under the Medicare operated prescription drug plan       (as defined in section 1860D-11A(d)). Such process shall be       efficient, impose minimal administrative burdens, and ensure       the timely procurement of medications. Medical necessity       shall be based on professional medical judgment, the medical       condition of the beneficiary, and other medical evidence.        ``(B) Consultation in development of process.--In       developing the appeals process under subparagraph (A), the       Secretary shall consult with consumer and patient groups, as       well as other key stakeholders, to ensure the goals described       in subparagraph (A) are achieved.''.  [[Page S5926]]                                ____________________     Mr. President, I ask unanimous consent that the text of  the bill be printed in the Record.   There being no objection, the text of the bill was ordered to be  printed in the Record, as follows:                                  S. 2650         Be it enacted by the Senate and House of Representatives of       the United States of America in Congress assembled,       SECTION 1. SHORT TITLE.         This Act may be cited as the ``Medicare Prescription Drug       Savings and Choice Act of 2019''.       SEC. 2. ESTABLISHMENT OF MEDICARE OPERATED PRESCRIPTION DRUG                     PLAN OPTION.         (a) In General.--Subpart 2 of part D of title XVIII of the       Social Security Act is amended by inserting after section       1860D-11 (42 U.S.C. 1395w-111) the following new section:              ``medicare operated prescription drug plan option         ``Sec. 1860D-11A.  (a) In General.--Notwithstanding any       other provision of this part, for each year (beginning with       2021), in addition to any plans offered under section 1860D-      11, the Secretary shall offer one or more Medicare operated       prescription drug plans (as defined in subsection (d)) with a       service area that consists of the entire United States and       shall enter into negotiations in accordance with subsection       (c) with pharmaceutical manufacturers to reduce the purchase       cost of covered part D drugs for eligible part D individuals       who enroll in such a plan.        ``(b) Enrollment.--Notwithstanding subparagraphs (C) and       (D) of section 1860D-1(b)(1), a Medicare operated       prescription drug plan offered under this section shall serve       as the default prescription drug plan for all part D       enrollees unless another prescription drug plan is selected.        ``(c) Negotiations.--Notwithstanding section 1860D-11(i),       for purposes of offering a Medicare operated prescription       drug plan under this section, the Secretary shall negotiate       with pharmaceutical manufacturers with respect to the       purchase price of covered part D drugs in a Medicare operated       prescription drug plan and shall encourage the use of more       affordable therapeutic equivalents to the extent such       practices do not override medical necessity as determined by       the prescribing physician. To the extent practicable and       consistent with the previous sentence, the Secretary shall       implement negotiation and incentive strategies similar to       those used by other Federal purchasers of prescription drugs       to reduce the purchase cost of covered Part D drugs, and       other strategies, as described in subsection (f), which may       include the use of a pricing scale based on an international       price index.        ``(d) Medicare Operated Prescription Drug Plan Defined.--      For purposes of this part, the term `Medicare operated       prescription drug plan' means a comprehensive prescription       drug plan that offers qualified prescription drug coverage       and access to negotiated prices described in section 1860D-      2(a)(1)(A). Such a plan may offer supplemental prescription       drug coverage in the same manner as other qualified       prescription drug coverage offered by other prescription drug       plans.        ``(e) Monthly Beneficiary Premium.--        ``(1) Qualified prescription drug coverage.--The monthly       beneficiary premium for qualified prescription drug coverage       and access to negotiated prices described in section 1860D-      2(a)(1)(A) to be charged under a Medicare operated       prescription drug plan shall be uniform nationally. Such       premium for months in 2021 and each succeeding year shall be       based on the average monthly per capita actuarial cost of       offering the Medicare operated prescription drug plan for the       year involved, including administrative expenses.        ``(2) Supplemental prescription drug coverage.--Insofar as       a Medicare operated prescription drug plan offers       supplemental prescription drug coverage, the Secretary may       adjust the amount of the premium charged under paragraph (1).        ``(f) Use of Negotiation and Benefit Design Incentives.--        ``(1) In general.--With respect to the operation of a       Medicare operated prescription drug plan and in negotiating       with respect to the purchase price of covered part D drugs in       such plan, the Secretary shall reward value, increase       appropriate use of drugs, and ensure patient safety and       access to medications.        ``(2) Role of ahrq.--The Director of the Agency for       Healthcare Research and Quality,  [[Page S5925]]       in coordination with the Administrator of the Centers for       Medicare & Medicaid Services, shall be responsible for       assessing the clinical benefit of covered part D drugs and       making recommendations to the Secretary regarding the       negotiated prices of covered drugs and any appropriate       tiering or incentive strategies under the plan. In conducting       such assessments and making such recommendations, the       Director shall carry out the following activities:        ``(A) Consider the comparable international price of such       drugs based upon the median retail list price of such drug       (which shall be, as practicable, the volume-weighted price       for comparable units and dosage forms) among a category of at       least the following peer reference countries: Canada, the       United Kingdom, France, Japan, Australia, and Germany.        ``(B) Consider safety concerns and post-market data,       including those identified by the Food and Drug       Administration and from national health registries.        ``(C) Use available data and evaluations, including from       research supported by the National Institutes of Health, with       priority given to randomized controlled trials, to examine       clinical effectiveness, comparative effectiveness, safety,       and enhanced compliance with a drug regimen.        ``(D) Use the same classes of drugs developed by United       States Pharmacopeia for this part.        ``(E) Consider evaluations made by--        ``(i) the Director under section 1013 of the Medicare       Prescription Drug, Improvement, and Modernization Act of       2003;        ``(ii) other Federal entities, such as the Secretary of       Veterans Affairs; and        ``(iii) other private and public entities, which may       include the Drug Effectiveness Review Project and Medicaid       programs.        ``(F) Consider recommendations made by the advisory       committee pursuant to paragraph (3)(F).        ``(G) Recommend to the Secretary those drugs in a class       that provide a greater clinical benefit, including fewer       safety concerns or less risk of side-effects, than another       drug in the same class.        ``(3) Use of advisory committee.--        ``(A) In general.--The Secretary shall establish and       appoint an advisory committee (in this paragraph referred to       as the `advisory committee')--        ``(i) to review petitions from drug manufacturers, health       care provider organizations, patient groups, and other       entities regarding negotiated prices; and        ``(ii) to recommend any changes in order to further       negotiations with respect to such prices.        ``(B) Composition.--Subject to subparagraph (C), the       advisory committee shall be composed of 9 members and shall       include representatives of physicians, pharmacists,       consumers, and others with expertise in evaluating       prescription drugs. The Secretary shall select members based       on their knowledge of pharmaceuticals and the Medicare       population. Members shall be deemed to be special Government       employees for purposes of applying the conflict of interest       provisions under section 208 of title 18, United States Code,       and no waiver of such provisions for such a member shall be       permitted.        ``(C) Banned individuals.--        ``(i) Drug company lobbyists.--No former registered drug       manufacturer lobbyist--         ``(I) may be appointed to the advisory committee; or        ``(II) may be employed by the advisory committee during the       6-year period beginning on the date on which the registered       lobbyist terminates its registration in accordance with       section 4(d) of the Lobbying Disclosure Act of 1995 (2 U.S.C.       1603(d)) or the agent terminates its status, as applicable.         ``(ii) Senior executives of law-breaking companies.--No       former senior executive of a covered entity (as defined in       clause (iii))--         ``(I) may be appointed to the Advisory Committee; or        ``(II) may be employed by the Advisory Committee during the       6-year period beginning on the later of--         ``(aa) the date of the settlement described in item (aa) of       clause (iii)(II); or        ``(bb) the date on which the enforcement action described       in item (bb) of such clause has concluded.        ``(iii) Covered entity.--The term `covered entity' means       any entity that is--         ``(I) a drug manufacturer; and        ``(II)(aa) operating under Federal settlement including a       Federal consent decree; or        ``(bb) the subject of an enforcement action in a court of       the United States or by an agency.         ``(D) Consultation.--The advisory committee shall consult,       as necessary, with physicians who are specialists in treating       the disease for which a drug is being considered.        ``(E) Request for studies.--The advisory committee may       request the Agency for Healthcare Research and Quality or an       academic or research institution to study and make a report       on a petition described in subparagraph (A)(i) in order to       assess cost-effectiveness, clinical effectiveness,       comparative effectiveness, safety, and compliance with a drug       regimen.        ``(F) Recommendations.--The advisory committee shall make       recommendations to the Director of the Agency for Healthcare       Research and Quality regarding the appropriate price at which       to begin negotiations on a part D drug pursuant to this       section.        ``(G) Limitations on review of manufacturer petitions.--The       advisory committee shall not review a petition of a drug       manufacturer under subparagraph (A)(i) with respect to a       covered part D drug unless the petition is accompanied by the       following:        ``(i) Raw data from clinical trials on the safety and       effectiveness of the drug.        ``(ii) Any data from clinical trials conducted using active       controls on the drug or drugs that are the current standard       of care.        ``(iii) Any available data on comparative effectiveness of       the drug.        ``(iv) Any other information the Secretary requires for the       advisory committee to complete its review.        ``(g) Informing Beneficiaries.--The Secretary shall take       steps to inform part D eligible individuals not previously       enrolled in a Medicare operated drug plan (including such       individuals who are newly eligible to enroll under this part)       regarding the enrollment of such individual in a Medicare       operated drug plan in accordance with this section, including       providing information in the annual handbook and adding       information to the official public Medicare website related       to prescription drug coverage available through this part.        ``(h) Application of All Other Requirements for       Prescription Drug Plans.--Except as specifically provided in       this section, any Medicare operated drug plan shall meet the       same requirements as apply to any other prescription drug       plan, including the requirements of section 1860D-4(b)(1)       relating to assuring pharmacy access.''.        (b) Conforming Amendments.--        (1) Section 1860D-3(a) of the Social Security Act (42       U.S.C. 1395w-103(a)) is amended by adding at the end the       following new paragraph:        ``(4) Availability of the medicare operated prescription       drug plan.--A Medicare operated prescription drug plan (as       defined in section 1860D-11A(d)) shall be offered nationally       in accordance with section 1860D-11A.''.        (2)(A) Section 1860D-3 of the Social Security Act (42       U.S.C. 1395w-103) is amended by adding at the end the       following new subsection:        ``(c) Provisions Only Applicable in 2006 Through 2020.--The       provisions of this section shall only apply with respect to       2006 through 2020.''.        (B) Section 1860D-11(g) of such Act (42 U.S.C. 1395w-      111(g)) is amended by adding at the end the following new       paragraph:        ``(8) No authority for fallback plans after 2020.--A       fallback prescription drug plan shall not be available after       December 31, 2020.''.        (3) Section 1860D-13(c)(3) of the Social Security Act (42       U.S.C. 1395w-113(c)(3)) is amended--        (A) in the heading, by inserting ``and medicare operated       prescription drug plans'' after ``Fallback plans''; and        (B) by inserting ``or a Medicare operated prescription drug       plan'' after ``a fallback prescription drug plan''.        (4) Section 1860D-16(b)(1) of the Social Security Act (42       U.S.C. 1395w-116(b)(1)) is amended--        (A) in subparagraph (C), by striking ``and'' after the       semicolon at the end;        (B) in subparagraph (D), by striking the period at the end       and inserting ``; and''; and        (C) by adding at the end the following new subparagraph:        ``(E) payments for expenses incurred with respect to the       operation of Medicare operated prescription drug plans under       section 1860D-11A.''.        (5) Section 1860D-41(a) of the Social Security Act (42       U.S.C. 1395w-151(a)) is amended by adding at the end the       following new paragraph:        ``(19) Medicare operated prescription drug plan.--The term       `Medicare operated prescription drug plan' has the meaning       given such term in section 1860D-11A(d).''.        (c) Rule of Construction.--Nothing in this section shall be       interpreted to supersede any other negotiation authority       granted to the Secretary under Federal law with respect to       prescription drug prices.       SEC. 3. IMPROVED APPEALS PROCESS UNDER THE MEDICARE OPERATED                     PRESCRIPTION DRUG PLAN.         Section 1860D-4(h) of the Social Security Act (42 U.S.C.       1305w-104(h)) is amended by adding at the end the following       new paragraph:        ``(4) Appeals process for medicare operated prescription       drug plan.--        ``(A) In general.--The Secretary shall develop a well-      defined process for appeals for denials of benefits under       this part under the Medicare operated prescription drug plan       (as defined in section 1860D-11A(d)). Such process shall be       efficient, impose minimal administrative burdens, and ensure       the timely procurement of medications. Medical necessity       shall be based on professional medical judgment, the medical       condition of the beneficiary, and other medical evidence.        ``(B) Consultation in development of process.--In       developing the appeals process under subparagraph (A), the       Secretary shall consult with consumer and patient groups, as       well as other key stakeholders, to ensure the goals described       in subparagraph (A) are achieved.''.  [[Page S5926]]                                ____________________   